Anika Therapeutics (ANIK) EBITDA (2010 - 2026)

Anika Therapeutics (ANIK) has reported EBITDA for 17 consecutive years, with $3.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 170.67% year-over-year to $3.0 million in Q2 2026; TTM through Jun 2026 was -$5.1 million, a 44.64% increase from a year earlier, with the FY2025 full-year figure at -$11.1 million, down 116.64% from the prior year.
• EBITDA was $3.0 million for Q2 2026 at Anika Therapeutics, up from -$5.5 million in the prior quarter.
• Over five years, EBITDA peaked at $24.7 million in Q4 2023 and troughed at -$12.6 million in Q1 2023.
• A 5-year average of -$787333.3 and a median of -$3.3 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 279.8% in 2022 and sank 3891.36% in 2025, its largest moves.
• Over 5 years, EBITDA stood at $16.4 million in 2022, then soared by 50.59% to $24.7 million in 2023, then slumped by 102.85% to -$705000.0 in 2024, then soared by 191.63% to $646000.0 in 2025, then soared by 357.28% to $3.0 million in 2026.
• The last three EBITDA figures came in at $3.0 million (Q2 2026), -$5.5 million (Q1 2026), and $646000.0 (Q4 2025), per Business Quant data.